Trials / Recruiting
RecruitingNCT07135323
AvertD Post-Approval Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,000 (estimated)
- Sponsor
- Prescient Medicine Holdings, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Opioid Used Disorder Risk Assessment | Determine the likelihood of Opioid Used Disorder prior to prescribing opioids |
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2031-11-01
- Completion
- 2031-11-01
- First posted
- 2025-08-22
- Last updated
- 2025-08-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT07135323. Inclusion in this directory is not an endorsement.